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Abstract
Background: Sivelestat, a neutrophil elastase inhibitor, was previously approved in Japan for the treatment of acute
lung injury associated with systemic inflammatory response syndrome. However, sivelestat produced inconsistent
therapeutic benefits. This study aimed to identify factors predicting the therapeutic effects of sivelestat.
Methods: We enrolled 53 mechanically ventilated patients who received sivelestat. The patients were classified as
effective (n = 28) if they were weaned from the ventilator within 28 days, or as ineffective groups (n = 25). Patient
characteristics were compared between these groups and multivariate logistic regression analysis was used to
identify predictive factors. A validation study was then conducted in sivelestat-free patients.
Results: A high red blood cell count and low hydrogen ion concentration were significantly associated with a
higher ventilator weaning rate in patients receiving sivelestat. The validation study revealed that the hydrogen ion
concentration value also significantly associated with ventilator weaning in patients who did not receive sivelestat.
Conclusions: Although hydrogen ion concentration was inversely associated with the ventilator weaning rate, it
did not predict sivelestat efficacy. This study indicated that acute lung injury patients with a high red blood cell
count would derive the most benefit from sivelestat administration.
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Background
Acute lung injury (ALI) is a complex disorder caused by in-
flammation in response to conditions such as pneumonia
and sepsis. ALI is characterized by a neutrophilic inflam-
matory response, associated with increased pulmonary
vascular permeability [1]. Neutrophil elastase (NE) is one
of the proteases released from the neutrophils that accu-
mulate in the lung [2]. It degrades lung connective tissues
and enhances lung vasopermeability, resulting in ALI.
Furthermore, NE increases the production of neutrophil
migration factor and is recognized as an important driver
of systemic inflammatory response syndrome (SIRS) [3].
Sivelestat is a selective NE inhibitor, which binds
directly to NE and inactivates it by a reversible acylation-
deacylation mechanism [4–6]. In addition, it relaxes vas-
cular smooth muscle [7]. Sivelestat was approved in Japan
as a therapeutic drug for ALI associated with SIRS, but is
also used in other situations. For example, perioperative
administration of sivelestat for esophagectomy improves
postoperative respiratory function and shortens the
duration of hospitalization and of mechanical ventilation
[8–12]. Moreover, sivelestat is administered for pediatric
cardiopulmonary bypass surgery because it attenuates the
perioperative inflammatory response [13]. Sivelestat also
shortens the duration of mechanical ventilation, intensive
care unit stay, and hospitalization due to severe respira-
tory failure after thoracic aortic surgery [14].
In a post-marketing clinical trial (phase IV) conducted
in Japan [4], the adjusted mean number of ventilator-
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free days (VFD) was significantly higher in the sivelestat
group than in the control group (P = 0.0022). However,
the Sivelestat Trial in ALI Patients Requiring Mechanical
Ventilation (STRIVE) study [15] did not identify a sig-
nificant increase in VFDs in the sivelestat group, as com-
pared with the control group, and the final analysis
revealed no effect of sivelestat on VFD (day 1–28). Fur-
thermore, the 180-day all-cause mortality was higher in
the sivelestat group than in the control group (P = 0.006).
This resulted in the discontinuation of this clinical trial
and sivelestat thus failed to receive approval in other
countries, such as the USA.
These trials [4, 15] found that the efficacy of sivelestat
was inconsistent and it would therefore be beneficial to
identify the factors determining the differential effects of
sivelestat in patients who respond to treatment, versus
the non-responders. The purpose of this case-control




The case-control study was conducted in compliance with
the Strengthening the Reporting of Observational Studies
in Epidemiology statement and the Declaration of
Helsinki. The protocol (H024-003) was approved by the
institutional review board at Kan-etsu hospital (Saitama,
Japan). Fifty-three patients on mechanical ventilation, who
were administered sivelestat in the hospital from April
2006 to March 2012, were enrolled in this study.
Study design
The patients were divided into two groups, according to
whether they were categorized as effective or ineffective.
Patients in the effective group were weaned from the ven-
tilator within 28 days. VFDs (the primary endpoint of the
phase IV study in Japan [14]) and all-cause mortality (the
primary endpoint of the STRIVE study [15]) were both
assessed within 28 days in these studies; we therefore used
a 28-day monitoring period in the present study.
Data from the day before sivelestat administration
were used for this analysis. If these were unavailable, we
used the data from two days before sivelestat administra-
tion or from the day of sivelestat administration. Vital
signs and SpO2 were not included in the analysis because
they were affected by concomitant drugs or ventilation.
We initially compared the effective and ineffection group
data. We subsequently identified predictive factors using
the multivariate analysis described below.
Validation
The fators identified using the approach described above
may predict the patient response to sivelestat or may rep-
resent independent prognostic indicators. To investigate
this, we conducted a validation study in the absence of
sivelestat. Patients who were using a medical ventilator
but were not administered sivelestat were enrolled in Kan-
etsu hospital from January 2013 to December 2014. We
excluded perioperative patients and those who had been
hospitalized for < 24 h from this study.
Patients were divided into two groups, depending on
whether they were weaned from the ventilator within
28 days (the weaning group) or not (the no weaning
group).
These groups were compared using the approach
described in Study design.
Statistics
We used statistical analyses to investigate which factors
predicted the therapeutic effect of sivelestat. We per-
formed an F-test to determine whether each factor ex-
hibited a homoscedastic distribution. A t-test was used
in the initial screening of the effective and ineffective
groups if the distribution showed homoscedasticity; if
not, Welch’s t-test was used. The numbers of male pa-
tients, sepsis, and DIC in the two groups were analyzed






Age(yr) 67.7 ± 14.5 77.0 ± 8.4 0.006 b
Male (%) 21 (75.0 %) 20 (80.0 %) 0.664 c
Sepsis (%) 8 (28.6 %) 13 (52.0 %) 0.082 c
DIC (%) 9 (32.1 %) 11 (44.0 %) 0.374 c
ALT(IU/L) 46.8 ± 38.9 29.3 ± 26.4 0.064 a
AST(IU/L) 67.3 ± 61.9 75.1 ± 119.1 0.772 b
LDH(IU/L) 569 ± 222 670 ± 744 0.350 b
ALP(IU/L) 306 ± 160 500 ± 829 0.315 b
γ-GTP(IU/L) 68.9 ± 80.2 40.2 ± 34.6 0.121 b
BUN(mg/dL) 31.9 ± 20.8 37.3 ± 21.6 0.353 a
Scr(mg/dL) 2.0 ± 2.7 2.1 ± 2.6 0.961 a
RBC(×104/μL) 376.1 ± 84.9 327.2 ± 72.1 0.029 a
WBC(/μL) 11,121 ± 7299 13,441 ± 8549 0.292 a
Neut(%) 88.4 ± 9.3 85.9 ± 10.3 0.607 a
Plt(×104/μL) 18.8 ± 9.8 16.0 ± 9.8 0.295 a
Alb(g/dL) 3.1 ± 2.0 2.4 ± 0.6 0.127 b
CRP(mg/dL) 19.6 ± 11.2 15.5 ± 9.4 0.168 a
[H+](×10−8) 3.639 ± 0.667 4.422 ± 0.936 0.001 b
PO2(mmHg) 93.2 ± 48.1 61.4 ± 24.7 0.004
b
PCO2(mmHg) 36.6 ± 9.3 47.7 ± 17.5 0.007
b
Dose(mg/kg/h) 0.216 ± 0.049 0.209 ± 0.046 0.785 a
The data were expressed as the mean ± standard deviation, except for the
number of males, sepsis, and DIC. The value of [H+] was calculated as
follows: [H+] = 10–pH
a: Student t-test, b: Welch’s t-test, c: Chi-square test
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using the Chi-square test. We then performed multivari-
ate logistic regression analysis (stepwise: likelihood ratio)
using SPSS® (SPSS Inc., Chicago, USA) to identify factors
that showed a significant association with a high mech-
anical ventilation weaning rate. We employed the step-
wise method because the method is suitable to control




The profiles of the effective (n = 28) and ineffective (n = 25)
patient groups are shown in Table 1. The age, hydrogen
ion concentration ([H+]), and PCO2 values were signifi-
cantly lower in the effective group than in the ineffective
group. In contrast, the red blood cell count (RBC) and PO2
were significantly higher in the effective group than in the
ineffective group. Other factors showed no statistically sig-
nificant differences between these groups.
We used the factors that differed significantly between
these study groups (age, RBC, [H+], PO2, and PCO2) to
perform multivariate logistic regression analysis. The re-
lationships between these factors are shown in Fig. 1.
The value of PO2 slightly correlated with that of [H
+].
The results of the multivariate logistic regression ana-
lysis are shown in Table 2.
Age and PCO2, which correlated with [H
+] and/or PO2,
were dropped from the process. Three factors (RBC, [H+],
and PO2) were therefore identified as candidates for the
prediction of the therapeutic effect of sivelestat.
Validation
The validation study included 105 patients receiving med-
ical ventilation in the absence of sivelestat in Kan-etsu hos-
pital from January 2013 to December 2014. The patient’s
age, sex, RBC, and [H+] values in these weaning and no
weaning groups are shown in Table 3. The [H+] value was
significantly higher in the no weaning ventilator group than
in the weaning group (P = 0.006) and there was no signifi-
cant difference in RBC between these groups (P = 0.13).
Discussion
Although the efficacy and safety of Sivelestat in the
Japanese patients was demonstrated in the phase III
double-blind study and the postparket study, the differ-
ence in the 28-day ventilator-weaning rate was only
13 % between the sivelestat and control group in the
postparket study and the negative results was reported
Fig. 1 The relationship between factors adopted in the main analysis. RBC: red blood cell, [H+]: hydrogen ion concentration, PO2: oxygen partial
pressure, PCO2: carbon dioxide partial pressure
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in the STRIVE study [4, 15, 16]. The reason why the effi-
cacy was small or negative would be the presence of the
responder and non-responder. Thus, we attempted to
identify factors predicting the therapeutic effects of sive-
lestat. This case-control study is the first trial to find
predictors of the therapeutic effect of sivelestat in pa-
tients with ALI associated with SIRS.
We initially evaluated the differences between the
effective (ventilator weaning) and ineffective groups of
patients who were administered with sivelestat. This
logistic regression analysis revealed that three factors,
[H+], RBC, and PO2, were significantly associated with
the mechanical ventilation weaning rate of these patients.
A predictive formula was developed:
ln y=1 − yð Þ ¼ 0:012  RBC − 1:194  Hþ½ 
þ 0:030  PO2− 1:412 ð1Þ
where y was the probability of a good response to sivele-
stat. According to this formula, a higher RBC, lower [H+],
and higher PO2 were associated with a greater probability
of a good therapeutic response to sivelestat.
Formula 1 allows calculation of the probability of sive-
lestat effectiveness in a patient using the values of these
predictive factors. The normal reference values for [H+],
RBC, and PO2 are 3.548 × 10
−8 (corresponding to a pH
of 7.45), 450 (× 104/μL), and 100, respectively. Substitu-
tion of these reference values into formula 1 produces a
probability of 94 %. If one of these factors ([H+], RBC,
or PO2) changed to 5.853 × 10
−8 (pH = 7.23), 221, or 8.3,
respectively, the probability was reduced to 50 %.
This indicated that PO2 was unlikely to modulate the
patient response to sivelestat significantly, because a
PO2 value of 8.3 is not realistic in the clinical situation.
On the other hand, [H+] and RBC may have greater effect
on sivelestat response because a [H+] value of 5.853 × 10−8
(pH = 7.23), or a RBC value of 221 are often observed in
hospitalized patients.
Respiratory failure induces severe acidosis, where pul-
monary CO2 elimination decreases (respiratory acidosis)
and/or an oxygen deficit (lactic acidosis) occurs. Our
findings suggested that as respiratory function declined,
sivelestat became less effective. Red blood cells transport
oxygen within the body and a reduced RBC therefore in-
dicates oxygen deficiency, which necessitates a longer
ventilation period.
Although we found two candidate predictive factors in
the first study, it was possible that these predicted venti-
lator weaning, regardless of sivelestat administration.
Thus, we conducted a validation study of [H+] and RBC
values in patients who did not receive sivelestat.
The mean [H+] value was significantly higher in the
no weaning group, as compared with the weaning group,
indicating that this parameter predicted ventilator wean-
ing, even in the absence of sivelestat. On the other hand,
RBC showed little effect on the weaning rate of these
patients, indicating that only RBC predicted the thera-
peutic effect of sivelestat.
Patients who received dialysis therapy were expected
to have variable RBC values. Then, we count number of
dialyzing patients in the case-control study. The num-
bers of dialyzing patients were 8 in the effective group
and 6 in the ineffective group. The ratio of the dialyzing
patients was not significantly different between the groups
(chi-square test, p = 0.706).
Because a few patients were administered sivelestat in
Kan-etsu hospital, the patient numbers of effective and in-
effective group were 28 and 25, respectively. Such small
sample size is limitation of this study. The study of large
sample size is needed.
Conclusion
Evaluated [H+], RBC and PO2 levels prior to sivelestat
administration predicted that it would produce less
therapeutic benefit. The RBC represented a particularly
valuable predictor of this therapeutic effect. ALI patients
with high RBC levels may be the best candidates for
sivelestat administration.
Table 2 Logistic regression analysis
B S.E. p-value AOR 95 % CI
RBC 0.012 0.006 0.044 1.012 1.000–1.024
[H+] −1.194 0.510 0.019 0.303 0.112–0.824
PO2 0.030 0.014 0.031 1.030 1.003–1.058
constant −1.412 2.856 0.621
B regression coefficient
S.E. standard error
AOR adjusted odds ratio
95 % CI 95 % confidence interval
Table 3 Profiles of the patients included in the validation study
Weaning ventilator group (n = 56) Non weaning ventilator group (n = 49) P
Basical data Age(yr) 77.5 ± 14.0 79.1 ± 9.8 0.521 b
Male (%) 29 (51.8 %) 35 (71.4 %) 0.040 c
Candidates RBC(×104/μL) 385.6 ± 72.9 361.7 ± 91.2 0.139 a
[H+](×10−8) 4.661 ± 1.534 6.158 ± 3.418 0.006 b
The data were expressed as the mean ± standard deviation, except for the number of males
The value of [H+] was calculated as follows: [H+] = 10–pH
a: Student t-test, b: Welch’s t-test, c: Chi-square test
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